June 11–14, 2026 | Stockholm, Sweden
EHA 2026 highlighted the continued evolution of hematology research across multiple disease areas from early-phase clinical development and real-world evidence to patient-focused analyses. BeOne Medicines was excited to present a broad scientific program with 37 accepted abstracts, including 2 oral presentations and 20 poster presentations, spanning clinical development, real-world evidence, and treatment considerations across diverse patient populations in B-cell malignancies. In addition, we were proud to sponsor an expertled symposium looking at the most critical questions driving present and future care in CLL.
For those who were unable to attend, or would like to revisit the science presented by BeOne, we invite you to explore the resources on our EHA congress pages.
37 
2 
20SEE DATA HIGHLIGHTS SUMMARY
EXPLORE FULL PRESENTATIONS
ACCESS BEONE EHA SYMPOSIUM
Event type: Sponsored symposium
Date & Time: June 11, 2026, 10:00–11:30 AM CEST
Event Details: Join an expert faculty as they step ahead of today’s challenges to explore key aspects of CLL patient management.
This session will explore:
Current treatment approaches in CLL
An overview of current CLL treatment strategies, the supporting evidence base, and how treatment decisions are individualized in clinical practice.
Bridging data gaps in CLL
An exploration of where evidence gaps remain in CLL and how innovative analytical approaches can help inform clinical decision-making.
Future perspectives on cure in CLL
An expert perspective on what cure could mean in CLL and what current evidence suggests may be achievable now and in the future.
Gain clinically relevant insights and up-to-date guidance to enhance outcomes for your patients with CLL.
BeOne EHA Symposium – Be one step ahead in CLL
Welcome and introduction
How should we treat CLL at present
How to bridge data gaps
How do we cure CLL in the future
Summary and close
Department of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY
Lymphoma Research Group, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia
Department of Internal Medicine, Center of Integrated Oncology Aachen Bonn Cologne Düsseldorf, University Hospital of Cologne, Cologne, Germany
